245 related articles for article (PubMed ID: 37952076)
1. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
Sheng G; Wang T; Gao Y; Wu H; Wu J
Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
4. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
5. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
Front Immunol; 2022; 13():888650. PubMed ID: 35572541
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
7. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
8. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
9. The N6-methyladenosine methylation landscape stratifies breast cancer into two subtypes with distinct immunological characteristics.
Chen Y; Hou Y; Li S; Qin W; Zhang J
Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13875. PubMed ID: 38797522
[TBL] [Abstract][Full Text] [Related]
10. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
[TBL] [Abstract][Full Text] [Related]
12. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
[TBL] [Abstract][Full Text] [Related]
14. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
15. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
[TBL] [Abstract][Full Text] [Related]
16. Identification of clinical prognostic features of esophageal cancer based on m6A regulators.
Wang H; Zhang Y; Chen L; Liu Y; Xu C; Jiang D; Song Q; Wang H; Wang L; Lin Y; Chen Y; Chen J; Xu Y; Hou Y
Front Immunol; 2022; 13():950365. PubMed ID: 36159855
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
18. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
19. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
20. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas.
Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X
Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
